Considering the Experimental use of Temozolomide in Glioblastoma Research.
Glioblastoma
Temozolomide
established cell lines
limitations of experimental systems
Journal
Biomedicines
ISSN: 2227-9059
Titre abrégé: Biomedicines
Pays: Switzerland
ID NLM: 101691304
Informations de publication
Date de publication:
04 Jun 2020
04 Jun 2020
Historique:
received:
06
05
2020
revised:
30
05
2020
accepted:
31
05
2020
entrez:
10
6
2020
pubmed:
10
6
2020
medline:
10
6
2020
Statut:
epublish
Résumé
Temozolomide (TMZ) currently remains the only chemotherapeutic component in the approved treatment scheme for Glioblastoma (GB), the most common primary brain tumour with a dismal patient's survival prognosis of only ~15 months. While frequently described as an alkylating agent that causes DNA damage and thus-ultimately-cell death, a recent debate has been initiated to re-evaluate the therapeutic role of TMZ in GB. Here, we discuss the experimental use of TMZ and highlight how it differs from its clinical role. Four areas could be identified in which the experimental data is particularly limited in its translational potential: 1. transferring clinical dosing and scheduling to an experimental system and vice versa; 2. the different use of (non-inert) solvent in clinic and laboratory; 3. the limitations of established GB cell lines which only poorly mimic GB tumours; and 4. the limitations of animal models lacking an immune response. Discussing these limitations in a broader biomedical context, we offer suggestions as to how to improve transferability of data. Finally, we highlight an underexplored function of TMZ in modulating the immune system, as an example of where the aforementioned limitations impede the progression of our knowledge.
Identifiants
pubmed: 32512726
pii: biomedicines8060151
doi: 10.3390/biomedicines8060151
pmc: PMC7344626
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
Nature. 2006 Dec 7;444(7120):756-60
pubmed: 17051156
EBioMedicine. 2015 Aug 15;2(10):1351-63
pubmed: 26629530
Arch Toxicol. 2012 Apr;86(4):651-61
pubmed: 22105179
Front Oncol. 2018 Oct 10;8:429
pubmed: 30364119
Bioorg Med Chem Lett. 2016 Oct 15;26(20):5103-5109
pubmed: 27614414
Cancer Chemother Pharmacol. 1990;26(6):429-36
pubmed: 2225314
Nat Rev Immunol. 2012 Nov;12(11):786-98
pubmed: 23059428
Front Oncol. 2020 Feb 14;10:89
pubmed: 32117743
Expert Opin Drug Metab Toxicol. 2013 Mar;9(3):237-52
pubmed: 23256482
Annu Rev Pathol. 2014;9:1-25
pubmed: 23937436
Clin Vaccine Immunol. 2010 Jan;17(1):143-53
pubmed: 19889936
J Neurooncol. 2003 Feb;61(3):203-7
pubmed: 12675312
Nature. 2012 Aug 23;488(7412):522-6
pubmed: 22854781
Cancer Res. 1998 Oct 1;58(19):4363-7
pubmed: 9766665
Cell Death Dis. 2014 Mar 27;5:e1145
pubmed: 24675463
FASEB J. 2020 Jan;34(1):1710-1727
pubmed: 31914660
Biomaterials. 2019 Apr;198:122-134
pubmed: 29941152
Clin Cancer Res. 2007 Jul 15;13(14):4271-9
pubmed: 17634557
Nat Rev Clin Oncol. 2018 Jul;15(7):422-442
pubmed: 29643471
Expert Opin Drug Metab Toxicol. 2006 Dec;2(6):875-94
pubmed: 17125407
Lancet Oncol. 2015 Oct;16(13):1324-34
pubmed: 26342236
Br J Cancer. 1992 Feb;65(2):287-91
pubmed: 1739631
J Clin Oncol. 2010 Apr 20;28(12):2051-7
pubmed: 20308655
Clin Cancer Res. 2009 Nov 15;15(22):7092-8
pubmed: 19861433
Cell Death Differ. 2006 Jul;13(7):1238-41
pubmed: 16456578
Cancer Cell. 2006 May;9(5):391-403
pubmed: 16697959
Oncotarget. 2017 Aug 11;8(40):69185-69197
pubmed: 28978189
ASN Neuro. 2011 Aug 03;3(3):e00063
pubmed: 21740400
Mol Cancer Ther. 2012 Nov;11(11):2440-50
pubmed: 22986464
Xenobiotica. 2004 May;34(5):487-500
pubmed: 15370964
PLoS One. 2015 Jun 29;10(6):e0131670
pubmed: 26121251
J Neurol. 2009 May;256(5):734-41
pubmed: 19240962
J Pharm Sci. 2016 Sep;105(9):2825-2831
pubmed: 27025982
Clin Cancer Res. 2005 May 15;11(10):3624-32
pubmed: 15897557
Sci Transl Med. 2016 Aug 31;8(354):354re3
pubmed: 27582061
Clin Cancer Res. 2019 Dec 1;25(23):7189-7201
pubmed: 31530630
Pediatr Blood Cancer. 2010 Oct;55(4):644-51
pubmed: 20589659
Cell Rep. 2013 Jan 31;3(1):260-73
pubmed: 23333277
Curr Biol. 2007 Jan 23;17(2):165-72
pubmed: 17196391
Clin Cancer Res. 2008 Dec 15;14(24):8205-12
pubmed: 19088037
Cancer Res. 2011 Sep 1;71(17):5932-40
pubmed: 21862632
J Neurooncol. 2017 Nov;135(2):343-351
pubmed: 28756593
Mol Cancer. 2010 Jun 01;9:135
pubmed: 20515495
Pharmacol Ther. 2013 Apr;138(1):103-41
pubmed: 23333322
Vaccines (Basel). 2016 Aug 06;4(3):
pubmed: 27509527
Br J Cancer. 2003 Apr 7;88(7):1004-11
pubmed: 12671695
Cancer Res. 2019 Jan 1;79(1):99-113
pubmed: 30361254
Proc Natl Acad Sci U S A. 2005 Jun 7;102(23):8287-92
pubmed: 15928080
Stem Cells Int. 2019 Jun 18;2019:6107456
pubmed: 31316566
Cancer Res. 2008 Jul 15;68(14):5706-15
pubmed: 18632623
Stem Cells. 2009 Apr;27(4):980-7
pubmed: 19353526
ScientificWorldJournal. 2011;11:1829-41
pubmed: 22125441
Neoplasia. 2008 Dec;10(12):1383-92
pubmed: 19048117
Cancers (Basel). 2017 May 26;9(6):
pubmed: 28587121
J Clin Invest. 2012 Jan;122(1):253-66
pubmed: 22156195
ACS Appl Mater Interfaces. 2015 Apr 1;7(12):6674-82
pubmed: 25751368
Brain Res Bull. 2017 Jan;128:34-39
pubmed: 27836802
Ann N Y Acad Sci. 1975 Jan 27;243:497-506
pubmed: 1055563
Neuro Oncol. 2016 Sep;18(9):1242-52
pubmed: 27009237
Sci Rep. 2016 Dec 21;6:39743
pubmed: 28000777
Sci Rep. 2019 Mar 15;9(1):4641
pubmed: 30874586
Front Immunol. 2018 May 08;9:1004
pubmed: 29867979
Clin Pharmacol Ther. 2020 May;107(5):1116-1127
pubmed: 31664714
Eur J Cancer. 1993;29A(7):940-2
pubmed: 8499146
Med Oncol. 2015 Mar;32(3):43
pubmed: 25631631
Neuro Oncol. 2012 Feb;14(2):132-44
pubmed: 22067563
Cell Death Differ. 2014 Jul;21(7):1119-31
pubmed: 24608791
Cell. 2020 Jan 9;180(1):188-204.e22
pubmed: 31883794
Int J Cancer. 2016 Apr 1;138(7):1709-18
pubmed: 26519239
Biochemistry. 1994 Aug 9;33(31):9045-51
pubmed: 8049205
Neuro Oncol. 2018 Nov 12;20(12):1566-1572
pubmed: 29733389
Neuro Oncol. 2011 Apr;13(4):393-400
pubmed: 21339188
Cancer Chemother Pharmacol. 1991;27(5):342-6
pubmed: 1998993
Clin Cancer Res. 2004 Jun 1;10(11):3728-36
pubmed: 15173079
Blood. 2011 Mar 17;117(11):3076-86
pubmed: 21252091
Lancet Oncol. 2009 May;10(5):459-66
pubmed: 19269895
Neuro Oncol. 2017 Aug 01;19(8):1097-1108
pubmed: 28204560
PLoS One. 2014 Sep 19;9(9):e107447
pubmed: 25238609
J Neurooncol. 2012 Sep;109(3):593-4; author reply 595
pubmed: 22772607
Cell Stress. 2019 Jan 23;3(2):47-65
pubmed: 31225500
Biochem Pharmacol. 2013 Mar 1;85(5):612-622
pubmed: 23063412
Cancer Cell. 2017 Mar 13;31(3):326-341
pubmed: 28292436
Biochem Pharmacol. 2003 Apr 1;65(7):1035-41
pubmed: 12663039
Cell Stem Cell. 2009 Jun 5;4(6):568-80
pubmed: 19497285
Mol Cancer Res. 2008 Aug;6(8):1268-75
pubmed: 18708359
Oncotarget. 2017 May 2;8(18):29865-29886
pubmed: 28415741
Invest Ophthalmol Vis Sci. 2007 Aug;48(8):3714-8
pubmed: 17652743
Int J Mol Sci. 2018 Sep 22;19(10):
pubmed: 30248992
FASEB J. 2014 Mar;28(3):1317-30
pubmed: 24327606
Cancer Res. 2010 Nov 15;70(22):9243-52
pubmed: 20935218
Neurology. 2004 Jun 8;62(11):2113-5
pubmed: 15184628
ACS Nano. 2019 Jan 22;13(1):97-113
pubmed: 30532951
Cancer Chemother Pharmacol. 2003 Dec;52(6):435-41
pubmed: 13680158
Oncogenesis. 2017 Nov 29;6(11):398
pubmed: 29184057
Clin Cancer Res. 2009 Dec 1;15(23):7186-95
pubmed: 19934306
Cancer Res. 1995 Jul 1;55(13):2853-7
pubmed: 7796412
Dis Model Mech. 2019 Sep 6;12(9):
pubmed: 31519690
Mol Cancer. 2010 Jul 20;9:194
pubmed: 20646316
Glia. 2019 May;67(5):779-790
pubmed: 30240060
Exp Hematol Oncol. 2014 Jan 23;3(1):3
pubmed: 24456704
Adv Funct Mater. 2020 Oct 28;30(44):
pubmed: 34211358
PLoS One. 2015 Jun 25;10(6):e0131441
pubmed: 26110872
J Neurooncol. 2017 May;132(3):401-407
pubmed: 28290002
PLoS One. 2015 Dec 23;10(12):e0145393
pubmed: 26700636
Trends Biotechnol. 2016 May;34(5):382-393
pubmed: 26838094
J Neuropathol Exp Neurol. 2006 Jun;65(6):529-39
pubmed: 16783163
Biomedicines. 2019 Sep 09;7(3):
pubmed: 31505812
Br J Cancer. 2016 Dec 6;115(12):1445-1450
pubmed: 27832665
Expert Rev Neurother. 2015;15(7):741-52
pubmed: 26027432
Sci Rep. 2017 Aug 18;7(1):8814
pubmed: 28821714
Mol Cancer Res. 2008 Jan;6(1):21-30
pubmed: 18184972
J Neurosci Methods. 2017 Apr 15;282:61-68
pubmed: 28284687
Neuro Oncol. 2009 Jun;11(3):281-91
pubmed: 18952979
Mol Med Rep. 2016 Feb;13(2):1329-35
pubmed: 26676970
Clin Cancer Res. 2017 Jul 15;23(14):3489-3498
pubmed: 28364015
Oncogene. 2014 Jun 26;33(26):3451-62
pubmed: 23912459
Mol Cancer Ther. 2012 Jun;11(6):1289-99
pubmed: 22532597
Neuro Oncol. 2014 Jul;16(7):896-913
pubmed: 24842956
Eur Rev Med Pharmacol Sci. 2002 Mar-Jun;6(2-3):33-44
pubmed: 12708608
Biomed Chromatogr. 2013 Jul;27(7):889-93
pubmed: 23436249
J Neurooncol. 2011 Mar;102(1):59-69
pubmed: 20623247
Stem Cells Dev. 2007 Oct;16(5):837-47
pubmed: 17999604
J Neurooncol. 2017 Dec;135(3):423-432
pubmed: 29052807
JCI Insight. 2016;1(2):
pubmed: 26973881
Clin Cancer Res. 2009 Nov 1;15(21):6541-50
pubmed: 19861460
Jpn J Clin Oncol. 2010 May;40(5):395-403
pubmed: 20364021
Cancer Biol Ther. 2009 Mar;8(5):452-7
pubmed: 19305157
Oncotarget. 2018 Oct 9;9(79):34935-34944
pubmed: 30405885
Cytometry. 1995 Jun 1;20(2):118-26
pubmed: 7664622
Cancer Res. 1994 Jul 15;54(14):3793-9
pubmed: 8033099
BMC Cancer. 2015 Apr 11;15:255
pubmed: 25886314
Science. 1982 Jul 9;217(4555):164-6
pubmed: 7089551
J Biol Chem. 2002 Mar 29;277(13):11352-61
pubmed: 11756412
ACS Nano. 2014 Jun 24;8(6):5494-514
pubmed: 24811110
Clin Cancer Res. 2013 Jun 1;19(11):2828-33
pubmed: 23580781
J Neurochem. 2012 Jul;122(2):444-55
pubmed: 22564186
Neuroscience. 2017 Jul 25;356:35-43
pubmed: 28526577
J R Soc Interface. 2014 Jul 6;11(96):
pubmed: 24829281
Neurobiol Dis. 2009 Apr;34(1):1-10
pubmed: 19100327
Oncotarget. 2013 Apr;4(4):502-30
pubmed: 23594434
Cancer Res. 1987 Nov 15;47(22):5846-52
pubmed: 3664486
Lab Invest. 2017 May;97(5):498-518
pubmed: 28287634
Neuro Oncol. 2012 Aug;14(8):979-93
pubmed: 22679124
Cancer Res. 2010 Apr 15;70(8):3228-38
pubmed: 20354191
Transl Oncol. 2019 Feb;12(2):320-335
pubmed: 30468988
Nature. 2018 Mar 15;555(7696):321-327
pubmed: 29489754
J Neurooncol. 2009 Sep;94(3):299-312
pubmed: 19381449
Mol Cancer Ther. 2016 Nov;15(11):2665-2678
pubmed: 27474153
Neuro Oncol. 2012 Nov;14 Suppl 5:v1-49
pubmed: 23095881
FEBS Open Bio. 2017 Feb 20;7(4):485-494
pubmed: 28396834
J Neuropathol Exp Neurol. 2018 Nov 1;77(11):1039-1054
pubmed: 30239918
Int J Cancer. 2015 Feb 15;136(4):E173-87
pubmed: 25123598
JCI Insight. 2018 Nov 2;3(21):
pubmed: 30385717
Neoplasia. 2010 Sep;12(9):727-39
pubmed: 20824049
J Clin Oncol. 2003 Apr 15;21(8):1624-36
pubmed: 12697889
J Neurochem. 2018 Jan;144(2):139-151
pubmed: 29164620
Genes Dev. 2019 Jun 1;33(11-12):591-609
pubmed: 31160393
Ageing Res Rev. 2018 May;43:17-25
pubmed: 29427795
Radiat Res. 2000 Oct;154(4):473-6
pubmed: 11023613
Mol Cancer. 2011 Oct 11;10:128
pubmed: 21988793
Nature. 2013 Oct 17;502(7471):333-339
pubmed: 24132290
Br J Cancer. 2018 Nov;119(10):1171-1181
pubmed: 30393372
Oncogene. 2008 Mar 27;27(14):2091-6
pubmed: 17934519
Mol Cancer. 2006 Dec 02;5:67
pubmed: 17140455
Cancer Res. 2009 Apr 15;69(8):3472-81
pubmed: 19351838
Biol Pharm Bull. 2002 Dec;25(12):1600-3
pubmed: 12499647
Int J Radiat Oncol Biol Phys. 2009 Sep 1;75(1):212-9
pubmed: 19695438
Front Immunol. 2019 Jul 23;10:1715
pubmed: 31396227
Cancer Chemother Pharmacol. 2019 Jan;83(1):81-89
pubmed: 30357450
J Immunother Cancer. 2019 Mar 28;7(1):85
pubmed: 30922400
Br J Cancer. 2013 Jan 15;108(1):64-71
pubmed: 23321511
J Neurochem. 2006 Feb;96(3):766-76
pubmed: 16405512
Biomedicines. 2020 Apr 20;8(4):
pubmed: 32326020
Toxicol Lett. 2004 Mar 14;148(1-2):91-4
pubmed: 15019092
Glia. 2001 Dec;36(3):375-90
pubmed: 11746774
Annu Rev Pathol. 2006;1:97-117
pubmed: 18039109
Br J Cancer. 2006 Nov 6;95(9):1155-60
pubmed: 17024124
Cancer Res. 2004 Oct 1;64(19):7011-21
pubmed: 15466194
J BUON. 2011 Jul-Sep;16(3):547-50
pubmed: 22006764
N Engl J Med. 2016 Sep 29;375(13):1289-94
pubmed: 27682039
Eur J Cancer. 1996 Dec;32A(13):2236-41
pubmed: 9038604
Fluids Barriers CNS. 2018 Jan 15;15(1):2
pubmed: 29332604
Curr Pathobiol Rep. 2015;3(3):219-223
pubmed: 26246962
Stem Cells. 2007 Jul;25(7):1645-53
pubmed: 17412894
Biomedicines. 2019 Nov 27;7(4):
pubmed: 31783653
J Transl Med. 2014 Apr 29;12:107
pubmed: 24779345
Clin Cancer Res. 1999 Feb;5(2):309-17
pubmed: 10037179
J Transl Med. 2014 Oct 04;12:278
pubmed: 25280402
Sci Rep. 2017 Jul 26;7(1):6602
pubmed: 28747713
Acta Neuropathol. 2017 Feb;133(2):263-282
pubmed: 28074274
Eur J Cancer. 1993;29A(7):1045-7
pubmed: 8499135
Cancer Chemother Pharmacol. 2014 Jul;74(1):185-93
pubmed: 24867782
Acta Neuropathol. 1981;53(1):21-8
pubmed: 7211194
Mol Cancer Ther. 2013 Feb;12(2):162-72
pubmed: 23243059
Clin Cancer Res. 2017 Feb 15;23(4):1080-1090
pubmed: 27551002
Curr Treat Options Oncol. 2019 Feb 21;20(3):24
pubmed: 30790064
J Neurooncol. 2012 Aug;109(1):45-52
pubmed: 22544650
Brain Pathol. 1999 Jul;9(3):469-79
pubmed: 10416987
Adv Mater. 2019 Apr;31(14):e1806590
pubmed: 30702785
Molecules. 2017 Nov 10;22(11):
pubmed: 29125561
N Engl J Med. 2005 Mar 10;352(10):987-96
pubmed: 15758009
Neuro Oncol. 2017 Jun 1;19(6):820-832
pubmed: 28062830
Biomedicines. 2019 Nov 11;7(4):
pubmed: 31717973
PLoS One. 2014 Aug 11;9(8):e104538
pubmed: 25111384
Histol Histopathol. 2009 Jul;24(7):879-91
pubmed: 19475534